CHAMPIONS ONCOLOGY, INC. Unbilled Receivables, Current
CHAMPIONS ONCOLOGY, INC. (CSBR) had Unbilled Receivables, Current of $5.94 million as of 2024-04-30, per its 10-K filed 2024-07-19.
Discontinued › Balance Sheet › Assets › Receivables, Net, Current
us-gaap:UnbilledReceivablesCurrent · last filed 2024-07-19
- 2024-04-30: Unbilled Receivables, Current $5.94M.
- 2023-04-30: Unbilled Receivables, Current $4.99M.
- 2022-04-30: Unbilled Receivables, Current $4.11M.
- 2018-04-30: Unbilled Receivables, Current $2.10M.
| Period end | Unbilled Receivables, Current |
|---|---|
| 2024-04-30 | $5.94M 10-K · filed 2024-07-19 |
| 2023-04-30 | $4.99M 10-K · filed 2024-07-19 |
| 2022-04-30 | $4.11M 10-K · filed 2024-07-19 |
| 2018-04-30 | $2.10M 10-K · filed 2018-07-30 |
| 2017-04-30 | $1.60M 10-K · filed 2018-07-30 |
| 2016-04-30 | $617.00K 10-K · filed 2017-07-28 |
| 2015-04-30 | $636.00K 10-K · filed 2016-07-29 |
| 2014-04-30 | $884.00K 10-K · filed 2015-07-29 |
| 2013-04-30 | $200.00K 10-K · filed 2014-07-28 |
| 2012-04-30 | $104.00K 10-K · filed 2013-07-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |